We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Grassley: Withheld Data May Have Affected Ketek Recommendations
Grassley: Withheld Data May Have Affected Ketek Recommendations
December 13, 2006
An FDA advisory committee may have voted against recommending approval of sanofi-aventis’ antibiotic Ketek if the agency had not withheld its concerns about clinical trial fraud from the members, Sen. Chuck Grassley (R-Iowa) said.